Top

Radiation Oncology

Published in:

Open Access 01-12-2018 | Research

The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation

Authors: Chengbo Ren, Tianlong Ji, Tingting Liu, Jun Dang, Guang Li

Published in: Radiation Oncology | Issue 1/2018

Abstract

Background

Thoracic reirradiation (re-RT) is increasingly administered. However, radiation pneumonitis (RP) remains to be the most common side effect from retreatment. This study aimed to determine the risk and predictors for severe RP in patients receiving thoracic re-RT.

Methods

Sixty seven patients with lung cancer received thoracic re-RT for recurrent or metastatic disease. Three-dimensional conformal radiotherapy (3D-CRT)/intensity modulated radiotherapy (IMRT) was used for 60 patients, and stereotactic body radiation therapy (SBRT) was used in 7 patients. Deformable image registration (DIR) was performed to create a composite plan. Severe (grade ≥ 3) RP was graded according to Common Terminology Criteria for Adverse Events version 4.0.

Results

Eighteen patients (26.9%) developed grade ≥ 3 RP (17 of grade 3, and 1 of grade 4). In univariate analyses, V5 and mean lung dose (MLD) of initial RT or re-RT plans, V5 and V20 of composite plans, and the overlap between V5 of initial RT and V5 of re-RT plans/V5 of re-RT plans (overlap-V5/re-V5) were significantly associated with grade ≥ 3 RP (P < 0.05 for each comparison). Multivariate analysis revealed that MLD of the initial RT plans (HR = 14.515, 95%CI:1.778–118.494, P = 0.013), V5 of the composite plans (HR = 7.398, 95%CI:1.319–41.495, P = 0.023), and overlap-V5/re-V5 (P = 0.041) were independent predictors for grade ≥ 3 RP. Out-of-field failures with medium overlap-V5/re-V5 of 0.4–0.8 was associated with higher risk of grade ≥ 3 RP compared with in-field failures (18.3% vs. 50%, P = 0.014).

Conclusions

The risk of grade ≥ 3 RP could be predicted not only by dose-volume variables from re-RT plan, but also by some from initial-RT and composite plans. Out-of-field failures was associated with higher risk of severe RP compared with in-field failures in some cases.

Vansteenkiste J, De Ruysscher D, Eberhardt WE, the ESMO Guidelines Working Group, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi89–98.CrossRefPubMed

Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced non small cell lung cancer. J Clin Oncol. 2007;25:4146–52.CrossRefPubMed

Socinski MA, Shcell MJ, Bakri K, et al. Second-line, low-dose, weekly paclitaxel in patients with stage III/A/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer. 2002;95:1265–73.CrossRefPubMed

Gonzalez CM, Aramendia JM, Salgado E, et al. Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer: a phase II study. Am J Clin Oncol. 2002;25:480–4.CrossRef

Serke M, Schoenfeld N, Loddenkemper R, et al. Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial. Anticancer Res. 2004;24:1211–6.PubMed

Kelly P, Balter PA, Rebueno N, et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010;78:1387–93.CrossRefPubMedPubMedCentral

Reyngold M, Wu AJ, McLane A, et al. Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). Radiat Oncol. 2013;8:99.CrossRefPubMedPubMedCentral

Griffioen GHMJ, Dahele M, De Haan PF, et al. High-dose, conventionally fractionated thoracic reirradiation for lung tumors. Lung Cancer. 2014;83:356–62.CrossRefPubMed

Okamoto Y, Murakami M, Yoden E, et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2002;52:390–6.CrossRefPubMed

10.

Ohguri T, Imada H, Yahara K, et al. Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: a potential modality for inducing long-term survival in selected patients. Lung Cancer. 2012;77:140–5.CrossRefPubMed

11.

Verma V, Rwigema JM, Malyapa RS, et al. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation. Radiother Oncol. 2017;125:21–30.CrossRefPubMed

12.

Parks J, Kloecker G, Woo S, et al. Stereotactic body radiation therapy as salvage for intrathoracic recurrence in patients with previously irradiated locally advanced non–small cell lung Cancer. Am J Clin Oncol. 2016;39:147–53.CrossRefPubMed

13.

Sumita K, Harada H, Asakura H, et al. Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study. Radiat Oncol. 2016;11:104.CrossRefPubMedPubMedCentral

14.

Trovo M, Minatel E, Durofil E, et al. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;88:1114–9.CrossRefPubMed

15.

Liu H, Zhang X, Vinogradskiy YY, et al. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84:1017–23.CrossRefPubMedPubMedCentral

16.

Senthi S, Griffioen GH, van Sörnsen de Koste JR, et al. Comparing rigid and deformable dose registration for high dose thoracic re-irradiation. Radiother Oncol. 2013;106:323–6.CrossRefPubMed

17.

Kaus MR, Brock KK, Pekar V, et al. Assessment of a model-based deformable image registration approach for radiation therapy planning. Int J Radiat Oncol Biol Phys. 2007;68:572–80.CrossRefPubMed

18.

Gravs PR, Siddiqui F, Anscher MS, et al. Radiation pulmonary toxicity: from mechanisms to management. Semin Radiat Oncol. 2010;20:201–7.CrossRef

19.

Wu K-L, Jiang G-L, Qian H, et al. Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial. Int J Radiat Oncol. 2003;57:1345–50.CrossRef

20.

Kruser TJ, McCabe BP, Mehta MP, et al. Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma. Am J Clin Oncol. 2014;37:70–6.CrossRefPubMedPubMedCentral

21.

De Bari B, Filippi AR, Mazzola R, et al. Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-doseprevious thoracic radiotherapy for lung malignancies. Cancer Treat Rev. 2015;41:511–8.CrossRefPubMed

22.

De Ruysscher D, Faivre-Finn C, Le Pechoux C, et al. High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. Lancet Oncol. 2014;15:e620–4.CrossRefPubMed

Title: The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation
Authors: Chengbo Ren
Tianlong Ji
Tingting Liu
Jun Dang
Guang Li
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-018-1016-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis

To propose adding index of achievement (IOA) to IMRT QA process

Radiation-induced parotid changes in oropharyngeal cancer patients: the role of early functional imaging and patient−/treatment-related factors

Feasibility of ipsilateral lower neck sparing irradiation for unilateral or bilateral neck node-negative nasopharyngeal carcinoma: systemic review and meta-analysis of 2, 521 patients

A remote EPID-based dosimetric TPS-planned audit of centers for clinical trials: outcomes and analysis of contributing factors

Monte Carlo simulations in radiotherapy dosimetry